Profile data is unavailable for this security.
About the company
Tibet Weixinkang Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of chemical pharmaceutical preparations and their active pharmaceutical ingredient. The Company's main products include multivitamins for injection (12), multi-trace element injection, pediatric multivitamin injection (13), compound electrolyte injection (V), potassium magnesium aspartate injection, potassium aspartate injection and other products. The Company is also engaged in pharmaceutical marketing services. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)1.17bn
- Net income in CNY222.08m
- Incorporated2006
- Employees689.00
- LocationTibet Weixinkang Pharmaceutical Co Ltd3F, Block 4, Industry Center, No. 5Yuanqu South Road, Zone B, Lasa EconomicLASA 850000ChinaCHN
- Phone+86 8 916601760
- Fax+86 8 916601760
- Websitehttps://www.wxkpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obio Technology Shanghai Corp Ltd | 244.64m | -294.16m | 4.60bn | 692.00 | -- | 3.02 | -- | 18.81 | -0.4578 | -0.4578 | 0.3819 | 2.35 | 0.1095 | 4.22 | 2.37 | 353,519.30 | -13.15 | -3.10 | -15.68 | -3.47 | -37.29 | 19.60 | -120.16 | -23.22 | 1.06 | -94.99 | 0.2068 | -- | 21.16 | 31.58 | -151.54 | -- | 36.17 | -- |
| Sinotherapeutics Inc | 480.48m | 98.59m | 4.63bn | 312.00 | 46.95 | 3.54 | -- | 9.63 | 0.2175 | 0.2175 | 1.06 | 2.89 | 0.333 | 2.74 | 4.51 | 1,539,987.00 | 6.83 | 10.22 | 7.32 | 11.26 | 43.78 | 65.76 | 20.52 | 31.88 | 11.08 | -- | 0.00002 | 13.77 | 70.61 | 29.80 | 109.09 | 94.07 | 32.01 | -- |
| Ningbo Menovo Pharmaceutical Co Ltd | 1.54bn | 99.48m | 4.67bn | 2.47k | 47.05 | 2.02 | -- | 3.03 | 0.4502 | 0.4502 | 7.00 | 10.49 | 0.329 | 1.23 | 5.91 | 623,207.90 | 2.34 | 3.98 | 3.68 | 6.21 | 32.03 | 34.08 | 7.11 | 12.00 | 0.7165 | 5.71 | 0.3482 | 11.27 | 12.85 | 3.07 | 476.64 | -15.04 | -11.37 | -8.68 |
| Shanghai Xiao Fang Pharmaceutical Co Ltd | 504.59m | 213.50m | 4.76bn | 404.00 | 22.17 | 4.51 | -- | 9.43 | 1.33 | 1.33 | 3.16 | 6.57 | 0.3795 | 3.71 | 4.85 | 1,248,981.00 | 16.06 | -- | 19.02 | -- | 65.40 | -- | 42.31 | -- | 3.47 | -- | 0.0017 | -- | 0.5748 | -- | 0.8074 | -- | -- | -- |
| Pulike Biological Engineering Inc | 1.10bn | 143.67m | 4.78bn | 1.55k | 32.87 | 1.86 | -- | 4.33 | 0.4204 | 0.4204 | 3.22 | 7.45 | 0.3571 | 2.68 | 3.03 | 711,690.80 | 4.65 | 6.79 | 5.41 | 8.00 | 57.65 | 62.55 | 13.02 | 16.34 | 2.51 | 15.83 | 0.0005 | 61.54 | -16.77 | 9.47 | -46.82 | -3.21 | 7.28 | 14.87 |
| Tibet Weixinkang Pharmaceutical Co Ltd | 1.17bn | 222.08m | 4.84bn | 689.00 | 21.67 | 3.17 | -- | 4.15 | 0.5136 | 0.5136 | 2.71 | 3.51 | 0.608 | 11.75 | 6.71 | 1,695,637.00 | 11.56 | 10.05 | 14.30 | 13.45 | 58.42 | 51.50 | 19.01 | 13.72 | 3.93 | -- | 0.0058 | 52.31 | -1.69 | 11.90 | 15.02 | 34.62 | 5.91 | 50.02 |
| Guizhou Sanli Pharmaceutical Co Ltd | 1.74bn | 160.68m | 4.90bn | 2.85k | 30.19 | 3.32 | -- | 2.82 | 0.3969 | 0.3969 | 4.26 | 3.61 | 0.5877 | 1.73 | 2.98 | 608,615.00 | 5.58 | 10.78 | 8.75 | 15.70 | 68.09 | 70.69 | 9.49 | 15.41 | 1.11 | 27.57 | 0.345 | 35.70 | 31.16 | 19.40 | -6.38 | 15.54 | 41.35 | -- |
| Shanghai New World Co Ltd | 1.10bn | 69.08m | 5.02bn | 1.14k | 72.75 | 1.18 | -- | 4.54 | 0.1067 | 0.1067 | 1.71 | 6.57 | 0.1962 | 3.93 | 11.76 | 968,234.30 | 1.22 | 0.6394 | 1.61 | 0.8838 | 40.39 | 36.38 | 6.20 | 3.58 | 1.56 | -- | 0.1118 | 71.59 | -1.21 | -7.49 | 121.22 | 13.84 | -26.50 | 5.92 |
| Jianmin Pharmaceutical Group Co Ltd | 3.18bn | 326.30m | 5.08bn | 2.35k | 15.36 | 1.97 | -- | 1.60 | 2.16 | 2.16 | 21.01 | 16.83 | 0.7435 | 3.94 | 3.46 | 1,354,202.00 | 7.77 | 10.96 | 12.83 | 19.58 | 60.52 | 44.41 | 10.45 | 10.23 | 1.40 | -- | 0.0438 | 37.54 | -16.81 | 9.38 | -30.54 | 31.68 | 11.66 | 35.10 |
Data as of Feb 13 2026. Currency figures normalised to Tibet Weixinkang Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 4.59m | 1.07% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2025 | 2.59m | 0.60% |
| CIB Fund Management Co., Ltd.as of 30 Jun 2025 | 1.61m | 0.37% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.45m | 0.34% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 313.50k | 0.07% |
| Mercer Global Investments Europe Ltd.as of 30 Jun 2025 | 147.60k | 0.03% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2025 | 131.60k | 0.03% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 110.40k | 0.03% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2025 | 96.50k | 0.02% |
| Nuode Asset Management Co., Ltd.as of 30 Jun 2025 | 80.00k | 0.02% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
